Search results
Vladimir MOISEYENKO | Cited by 9,668 | of National Cancer Institute Thailand, Bangkok (NCI) | Read 112 publications | Contact Vladimir MOISEYENKO
- Vladimir Moiseyenko's research while affiliated with Saint Petersburg ...
Vladimir Moiseyenko's 57 research works with 1,764 citations...
- Vladimir Moiseyenko's research while affiliated with Saint Petersburg ...
Jun 20, 2021 · Equivalent efficacy was demonstrated for the biosimilar CT-P6 and trastuzumab following neoadjuvant therapy for patients with human epidermal growth factor receptor-2 (HER2)-positive early breast cancer. Following adjuvant treatment, efficacy and safety were comparable between treatments.
Vladimir Moiseenko was born on 7 March 1963 in Magnitogorsk, Chelyabinsk Oblast, Russian SFSR, USSR [now Russia]. He was a writer, known for The Return (2003), 12 (2007) and Antidur (2007). He died on 22 March 2011.
Sep 22, 2020 · Neoadjuvant immune checkpoint blockade demonstrated promising results in a number of trials involving various categories of patients with cancer; therefore, we considered feasible to offer preoperative nivolumab to a patient with T3N1M0 MSI-H GC.
Dec 14, 2015 · Once-per-cycle balugrastim is a safe and effective alternative to pegfilgrastim for hematopoietic support in patients with breast cancer receiving myelosuppressive chemotherapy associated with a greater than 20% risk of developing febrile neutropenia.
Sep 22, 2020 · Locally advanced gastric cancer (GC) is often managed by neoadjuvant chemotherapy and surgery; however, pathological complete responses to preoperative systemic treatment are rare.
Vladimir Moiseyenko's 57 research works with 1,764 citations and 5,641 reads, including: A phase 1b study of the allosteric extracellular FGFR2 inhibitor alofanib in patients with pretreated ...
